Preferential Rights Issue / Företrädesemission 2018
Alzinova carried out a preferential rights issue of SEK 30.1 million before costs, together with a directed rights issue of SEK 15.0 million before costs, to finance the clinical development program of ALZ-101. Below you will find information in regards to this issue and the prospectus.
- Read the full prospectus
- Read the “teaser”/short folder
- Company presentation / bolagsbeskrivning, when listed at Nasdaq North Growth Market
- Press release 16 Nov. 2018, publication prospectus / offentliggörande prospekt
- Press release 10 Dec. 2018, outcome of rights issue / utfall av företrädesemission